Medical News / ASRS 2021 - Arshad Khanani, MD, MA: Applying Ranibizumab PDS in Practice

In the coming weeks, the US Food and Drug Administration (FDA) will be considering the application for ranibizumab delivered via port delivery system (PDS) for the treatment of patients with neovascular age-related macular degeneration (nAMD). The timing for a potential approve aligns perfectly with expert discussion being hosted at a pair of national ophthalmology meetings this month, the first being the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting this week. In fact, new data from the phase 3 Archway trial presented at ASRS showed the uniquely-delivered anti-VEGF therapy is not impacted by patient retinal fluid rates. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
Real-world registry data presented this weekend at the American Society of Retina Specialists (ASRS) 2021 Scientific ... read more
The design of the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting came to represent ... read more
Approximately 15 years into the era of anti-VEGF therapies for the treatment of age-related macular degeneration ... read more
Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends ... read more